HERAMED LIMITED — Director's Dealing 2019

Nov 27, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity HeraMED Limited

ABN 65 626 295 314

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Tal Slonim
Date of last notice	11 December 2018

Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Altshuler Shaham Trusts Ltd<Tal Slonim A/C>(beneficial holder)
Date of change	28 November 2019
No. of securities held prior to change	7,995,723 Ordinary fully paid ordinaryshares escrowed 24 months fromquotation3,187,500 Unlisted options @ $0.25 expiring5/12/21 escrowed 24 months fromquotation463,752 Unlisted options @ $0.00002expiring5/12/21escrowed24months from quotation
Class	Ordinary fully paid ordinary shares escrowed24 months from quotation
Number acquired	1,249,695

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Number disposed	-	-	-
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	alue/Considerationte: If consideration is non-cash, provide details and estimated		Deferred Consideration Shares issued to
	luation		he vendors (and/or their nominees) aspart of the Acquisition – refer Section
		7.1(b)(ii) of the Prospectus dated 15/10/18.The securities have been issued uponmeeting the performance milestone being
		r	eceipt of the FDA approval, which was
			announced on 18/11/19.
No. of securities held after change	o. of securities held after change		9245418 Ordinary fully paid ordinary
			,,shares escrowed 24 months from
		quotation3,187,500 Unlisted options @ $0.25 expiring5/12/21 escrowed 24 months fromquotation463,752 Unlisted options @ $0.00002expiring5/12/21escrowed24months from quotation
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back		Deferred Consideration Shares issued tothe vendors (and/or their nominees) aspart of the Acquisition – refer Section7.1(b)(ii) of the Prospectus dated 15/10/18.The securities have been issued uponmeeting the performance milestone beingreceipt of the FDA approval, which wasannounced on 18/11/19.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	N/A
If so, was prior written clearance provided to allow the tradeto proceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3